Illumina, Affymetrix, Keygene, University Medical Center Utrecht, NIH, NCI, National Research Council, New England Journal of Medicine | GenomeWeb
Illumina to Pay Affy $90M to Settle Patent Suits, Cease Litigation
 
Illumina said last week that it will pay Affymetrix $90 million to settle all ongoing patent lawsuits between the two companies, and that both firms have agreed to a covenant not to sue for use of current and future products.
 
The agreement ends patent litigation between the companies in the US, Germany, and the UK dating back to 2004.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.